N/A
Completed N=631
Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)
Cancer Treated With Immune-checkpoint Inhibitors
Source: ClinicalTrials.gov NCT03963518 ↗
Enrolled (actual)
631
Serious AEs
—
Results posted
Sep 2025
Primary outcomePrimary: Correlation Between Time to Next Treatment or Death (TNT-D) and Overall Survival (OS) — 0.63; 0.66 correlation coefficient
Summary
Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Correlation Between Time to Next Treatment or Death (TNT-D) and Overall Survival (OS) |
0.63; 0.66 | — |
Eligibility Criteria
previously untreated advanced melanoma patients.
Data sourced from ClinicalTrials.gov (NCT03963518). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.